VTGN Stock Summary and Trading Ideas (Vistagen Therapeutics | NASDAQ:VTGN)

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.

As of December 13, 2024, VTGN stock price declined to $2.43 with 124,693 million shares trading.

VTGN has a beta of 1.21, meaning it tends to be more sensitive to market movements. VTGN has a correlation of 0.06 to the broad based SPY ETF.

VTGN has a market cap of $67.66 million. This is considered a Micro Cap stock.

Last quarter Vistagen Therapeutics reported $183,000 in Revenue and -$.42 earnings per share. This fell short of revenue expectation by $-37,000 and missed earnings estimates by -$.03.

In the last 3 years, VTGN traded as high as $63.30 and as low as $1.62.

The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL, IWC, AVSC.

VTGN has underperformed the market in the last year with a price return of -44.4% while the SPY ETF gained +31.7%. VTGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.8% and -9.7%, respectively, while the SPY returned +8.4% and +0.9%, respectively.

VTGN support price is $2.38 and resistance is $2.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.